PTC INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates PTC Therapeutics, Inc. for Possible Securities Fraud

NEW ORLEANS--()--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into PTC Therapeutics, Inc. (NasdaqGS: PTCT).

“that the application was not sufficiently complete to permit a substantive review.”

On February 23, 2016, PTC disclosed that it has received a Refuse to File letter from the United States Food and Drug Administration (FDA) regarding PTC’s New Drug Application (NDA) for Translarna for the treatment of muscular dystrophy. PTC further disclosed that the FDA’s Refuse to File letter stated “that the application was not sufficiently complete to permit a substantive review.”

On this news, the price of PTC’s shares plummeted by over 61%.

KSF’s investigation is focusing on whether PTC and/or its officers and directors violated state or federal securities laws.

If you are a PTC shareholder and have suffered losses, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit


Kahn Swick & Foti, LLC
Lewis Kahn, 1-877-515-1850
Managing Partner

Recent Stories

RSS feed for Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC